Insmed Incorporated

As of June 30, 2026, Insmed Incorporated carries a market capitalization of 20.09B, placing it among publicly traded companies globally. Its enterprise value stands at 19.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Insmed Incorporated's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Insmed Incorporated has 218.28M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.83, and the price-to-book ratio stands at 30.29.

These figures are as of June 30, 2026. The EV/Sales ratio of 19.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.58B versus a market cap of 20.09B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Insmed Incorporated maintains a current ratio of 3.72, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.55, indicating elevated leverage, while an interest coverage ratio of -10.83 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Insmed Incorporated posted a negative return on equity (ROE) of -87.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -38.20, reflecting losses generated across the asset base. The company generates approximately 635,971.21 in revenue per employee across its workforce of 1,565.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.51 indicates how many times Insmed Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Insmed Incorporated recorded 5.43M in income tax expense. The company reported a pretax loss of -760.73M and -766.16M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 97.52, while the 200-day moving average is 107.07.

Over the twelve months ended June 30, 2026, Insmed Incorporated generated 995.77M in revenue and converted that into -766.16M in net income, yielding earnings per share of -3.57. EBITDA reached -718.44M, while operating income came in at -711.31M.

As of June 30, 2026, Insmed Incorporated holds 1.02B in cash and equivalents against 507.57M in total debt, resulting in a net debt position of -1.10M. Total book value stands at 663.03M, with working capital of 1.05B providing operational flexibility.

Insmed Incorporated produced -681.79M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -25.16M in capital expenditures, free cash flow totaled -706.95M - equivalent to -3.29 per share.

Over the twelve months ended June 30, 2026, Insmed Incorporated posted a gross margin of 83.46, reflecting its pricing power and cost economics. The operating margin of -71.43 and net profit margin of -76.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -3.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.54, meaning Insmed Incorporated raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Insmed Incorporated's most recent stock split took place on March 3, 2011 with a 10:1 split ratio.

As of June 30, 2026, Insmed Incorporated has an Altman Z-Score of 5.83, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.